At the 2025 ITMIG (International Thymic Malignancy Interest Group) conference in Milan, Dr Véronique Hofman presented a study on FGFR1 gene amplification in thymic epithelial tumours (TET).
A step forward in understanding thymic tumours
TET are rare and have variable prognoses, requiring systemic treatment in advanced stages. The study presented analysed FGFR1 gene amplification, a potential therapeutic target, in 48 TETs and correlated it with clinical, pathological and prognostic data. FGFR1, potentielle cible thérapeutique, dans 48 TET et la corrélation avec les données cliniques, pathologiques et pronostiques
A national collaborative effort
This project was conducted with the French RYTHMIC network, certified by INCa, which brings together clinicians and pathologists specialising in the management of thymic tumours. This collaboration is helping to improve knowledge about these rare cancers and guide future diagnostic and therapeutic strategies.
A leading international scientific event
Dr Hofman's presentation is part of the multidisciplinary programme of ITMIG 2025, which brings together international experts every year to share advances in the diagnosis and treatment of thymic tumours.
